Restoring or augmenting immunity by the adoptive transfer of in vitro cultured antigen-specific T-cells has proven therapeutically effective for viral infections and tumors in animal models, and should be applicable to treatment of viral and malignant disease in man in situations in which human T-cells specific for virally encoded or tumor-derived antigens can be isolated. Preclinical studies in our laboratory have shown the presence of cytomegalovirus (CMV)-specific cytotoxic T-cells (Tc) in bone marrow transplant (BMT) recipients correlates with resistance to CMV infection, and studies in murine models have demonstrated that adoptive transfer of class I MHC-restricted CMV-specific Tn can prevent and/or treat severe CMV infection in immunocompromised hosts. We have developed the technology to generate and expand human CMV-specific CD8+ Tc and CD4+ T helper (Th) clones in vitro from seropositive marrow donors, and have initiated clinical studies to evaluate the safety of administering these clones to BMT recipients. Our studies to develop adoptive immunotherapy have been initiated with a viral disease since this permits the generation of T-cell clones with defined antigen specificity, thereby facilitating definition of the principles of effective adoptive transfer of immunity. Studies are proposed to expand these studies to include therapy of HIV in the post BMT setting, and our long range goal is to broaden the application of this approach to the therapy of human tumors. The illustration that tumor- derived immunoglobulin idiotype (Id) in B cell lymphomas can serve as a unique tumor antigen and elicit Id-specific T-cell responses has identified a situation in which we can now propose to explore immunotherapy with T- cell clones for the prevention of posttransplant relapse of a malignancy.
The specific aims of this project are 1) to evaluate specific immunological reconstitution in BMT recipients by adoptive immunotherapy with CMV- specific T-cell clones as prophylaxis or therapy for CMV infection, 2) to develop adoptive immunotherapy with CD8+ HIV-specific T-cell clones for HIV seropositive BMT recipients, including the use of retroviral-mediated gene transfer to introduce into these clones a selectable marker gene and a """"""""suicide"""""""" gene (herpes virus thymidine kinase) to increase the safety therapy in this setting, and 3) to develop posttransplant tumor-specific immunotherapy with CD4+ T-cell clones recognizing tumor-derived Id for patients receiving allogeneic BMT for B cell lymphomas.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications